1P5 Stock Overview
PAVmed Inc. operates as a medical device company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PAVmed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.27 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$1.22 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -63.88% |
| 3 Year Change | 64.08% |
| 5 Year Change | n/a |
| Change since IPO | 10.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1P5 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | -1.7% |
| 1Y | -63.9% | -11.0% | -0.2% |
Return vs Industry: 1P5 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 1P5 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1P5 volatility | |
|---|---|
| 1P5 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1P5 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1P5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 89 | Lishan Aklog | www.pavmed.com |
PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring.
PAVmed Inc. Fundamentals Summary
| 1P5 fundamental statistics | |
|---|---|
| Market cap | €70.54m |
| Earnings (TTM) | -€83.71m |
| Revenue (TTM) | €549.86k |
128.5x
P/S Ratio-0.8x
P/E RatioIs 1P5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1P5 income statement (TTM) | |
|---|---|
| Revenue | US$565.00k |
| Cost of Revenue | US$2.44m |
| Gross Profit | -US$1.87m |
| Other Expenses | US$84.15m |
| Earnings | -US$86.02m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -331.33% |
| Net Profit Margin | -15,224.25% |
| Debt/Equity Ratio | 124.3% |
How did 1P5 perform over the long term?
See historical performance and comparison